SI-BONE, Inc. (NASDAQ:SIBN) CFO Anshul Maheshwari Sells 1,733 Shares of Stock

SI-BONE, Inc. (NASDAQ:SIBN) CFO Anshul Maheshwari sold 1,733 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $17.59, for a total value of $30,483.47. Following the completion of the sale, the chief financial officer now directly owns 148,738 shares of the company’s stock, valued at approximately $2,616,301.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Anshul Maheshwari also recently made the following trade(s):

• On Monday, October 2nd, Anshul Maheshwari sold 1,244 shares of SI-BONE stock. The shares were sold at an average price of $21.15, for a total value of $26,310.60.

SI-BONE Stock Performance

Shares of SI-BONE stock opened at $18.04 on Tuesday. The business’s fifty day simple moving average is $18.93 and its 200 day simple moving average is $22.72. The firm has a market capitalization of $730.64 million, a P/E ratio of -15.16 and a beta of 0.99. SI-BONE, Inc. has a 12 month low of $11.14 and a 12 month high of $29.51. The company has a current ratio of 10.89, a quick ratio of 9.74 and a debt-to-equity ratio of 0.21.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Truist Financial dropped their target price on SI-BONE from $33.00 to $31.00 and set a “buy” rating on the stock in a report on Tuesday, August 8th. Morgan Stanley dropped their target price on SI-BONE from $30.00 to $25.00 and set an “overweight” rating on the stock in a report on Tuesday, November 7th. Cantor Fitzgerald dropped their target price on SI-BONE from $30.00 to $25.00 and set an “overweight” rating on the stock in a report on Tuesday, November 7th. Finally, Needham & Company LLC dropped their price target on SI-BONE from $32.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, November 7th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $27.17.

Institutional Trading of SI-BONE

Hedge funds have recently bought and sold shares of the business. Harbor Capital Advisors Inc. bought a new stake in SI-BONE during the second quarter worth $47,000. Coppell Advisory Solutions LLC bought a new stake in shares of SI-BONE in the second quarter valued at $50,000. FMR LLC raised its stake in shares of SI-BONE by 28.7% in the first quarter. FMR LLC now owns 2,160 shares of the company’s stock valued at $42,000 after buying an additional 482 shares during the period. Larson Financial Group LLC bought a new stake in shares of SI-BONE in the first quarter valued at $49,000. Finally, RiverPark Advisors LLC bought a new stake in shares of SI-BONE in the third quarter valued at $55,000.

About SI-BONE

SI-BONE, Inc, a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma.